Clinical Trials Logo

Clinical Trial Summary

Identification and localization of pathological parathyroid gland before parathyroidectomy is traditionally done by a combination of two methods: ultrasound and sestamibi scan. The investigators would like to show that one exam that includes ultrasound and fine needle aspiration of the parathyroid gland for parathyroid hormone level is as accurate as the traditional method.


Clinical Trial Description

A prospective, open label, single arm trial that includes participants that suffer hypercalcemia due to primary hyperparathyroidism and are candidates for parathyroidectomy. participants visit the investigator's head and neck clinic. the investigator confirms that the participant has an indication for parathyroidectomy according to the official criteria. Later on, the investigator looks at the localization tests that have already been done (neck ultrasound and MIBI [methoxyisobutyllisonitrile] scan) in order to plan the surgery. In case participant has not made those tests- the investigator fills a written request to do so. then, the investigator will perform a neck ultrasound and identifies the pathological parathyroid gland. The suspected pathological gland is aspirated using a 27 gauge needle attached to a 5 cc syringe fills with 1 cc saline (0.9% NaCL) under the guidance of the ultrasound. The aspirated material is sent for 2 examinations: 1. parathyroid hormone level: the aspirated material is injected into a ethylenediaminetetraacetic acid (EDTA) vial and send to the hospital's endocrine laboratory. the parathyroid hormone level is processed using chemiluminescence method and represented in Pg/ml units. 2. cytology examination. The aspirated material is spread on a glassed slide and prepared with a Giemsa stain for a cytologic examination. cytologic features such as cell type, cytoplasmic characteristics,cell block structure and chromatin appearance is addressed by the pathologist. After completion of the ultrasound - guided needle aspiration the participant is given an exact date for the surgery. The surgery is carried out routinely with the same surgical steps that the investigator is familiar with. At the end of surgery, after the pathological parathyroid gland was extracted from the neck, it is aspirated with a 27Gy needle attached to a 5 cc, syringe filled with a 1 cc saline (0.9% NaCL). The aspirated material is sent to the same, above mentioned, examinations (parathyroid hormone level and cytology). After the investigator receives the final pathological result of the suspected gland and confirm that the excised tissue was indeed a pathological parathyroid one, the investigators are able to answer 2 important questions: 1. Is high level of parathyroid hormone which was aspirated from a suspected pathological parathyroid tissue is a good indicator that the tissue is indeed a pathological parathyroid. 2. Is there a difference between parathyroid cytology of a tissue aspirated transcutaneously to a parathyroid cytology of material aspirated directly from the parathyroid gland. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03516747
Study type Interventional
Source HaEmek Medical Center, Israel
Contact
Status Withdrawn
Phase N/A
Start date June 9, 2018
Completion date August 9, 2020

See also
  Status Clinical Trial Phase
Withdrawn NCT02711059 - Insulin Resistance in Primary Hyperparathyroidism N/A
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Terminated NCT01725113 - Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Phase 4
Completed NCT01460030 - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Phase 3
Completed NCT00325104 - Cinacalcet to Treat Familial Primary Hyperparathyroidism Phase 3
Recruiting NCT03935984 - Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity Phase 4
Withdrawn NCT01329666 - Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D Phase 2/Phase 3
Completed NCT00891813 - Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Phase 4
Completed NCT00674154 - Effect of Vitamin D Treatment in Primary Hyperparathyroidism Phase 2/Phase 3
Completed NCT04299425 - Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Completed NCT00975221 - Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy Phase 3
Completed NCT00485706 - Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients N/A
Recruiting NCT01647503 - Differentially Expressed Proteins in Sporadic Parathyroid Tumors N/A
Completed NCT01042626 - Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects N/A
Not yet recruiting NCT01021280 - Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome N/A
Not yet recruiting NCT01226810 - The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration N/A
Terminated NCT00415584 - Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients Phase 1/Phase 2
Completed NCT00581828 - Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Phase 4
Completed NCT00126386 - Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community N/A
Recruiting NCT05152927 - Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A